Celcuity Stock Quote CELC - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

17.67

Bid

10.50

Ask

23.52

Volume

284,562

17.295 Day's Range 17.97

8.389 52 Week Range 22.188

Market Cap

428.154M

Previous Close

17.66

Open

17.83

Last Trade

793

17.67

(formt)

Last Trade Time

Financial Volume

$ 5,035,946

VWAP

17.6972

Average Volume (3m)

246,462

Shares Outstanding

24,203,156

Dividend Yield

PE Ratio

-6.71

Earnings Per Share (EPS)

-2.64

Revenue

Net Profit

-63.78M

Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered ... Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Show more

Sector

Medical Laboratories

Industry

Medical Laboratories

Website

www.celcuity.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Celcuity Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker CELC. The last closing price for Celcuity was $17.66. Over the last year, Celcuity shares have traded in a share price range of $ 8.389 to $ 22.188.

Celcuity currently has 24,203,156 shares outstanding. The market capitalization of Celcuity is $428.15 million. Celcuity has a price to earnings ratio (PE ratio) of -6.71.

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical...

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...

Form 4 - Statement of changes in beneficial ownership of securities

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first...

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.75	10.9924623116	15.92	17.99	14.63	321706	16.18704276	CS
4	-2	-10.1677681749	19.67	20.15	14.63	200237	17.16755759	CS
12	3.3	22.9645093946	14.37	22.188	13.74	246462	17.65803472	CS
26	7.39	71.8871595331	10.28	22.188	9.99	183627	16.48719468	CS
52	8.22	86.9841269841	9.45	22.188	8.389	129619	14.66221193	CS
156	-10.83	-38	28.5	33.01	4.81	85722	14.54827148	CS
260	-4	-18.4586986617	21.67	33.01	4.03	75257	16.39184766	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BENFBeneficient	$ 6.8001 (254.17%)	31.01M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M
SHOTWSafety Shot Inc	$ 0.45 (45.16%)	644
AIPArteris Inc	$ 8.185 (38.03%)	1.11M
RGFReal Good Food Company Inc	$ 0.85 (37.32%)	4.26M
MNDRMobile health Network Solutions	$ 3.33 (-84.91%)	18.76M
NUVOHoldco Nuvo Group DG Ltd	$ 2.00 (-57.54%)	1.04M
SPTSprout Social Inc	$ 28.82 (-40.15%)	13.47M
UNITUniti Group Inc	$ 4.441 (-26.35%)	21.07M
IPDNProfessional Diversity Network Inc	$ 1.29 (-24.12%)	662.59k
AAPLApple Inc	$ 183.38 (5.98%)	163.22M
SQQQProShares UltraPro Short QQQ	$ 11.08 (-5.94%)	154.59M
JAGXJaguar Health Inc	$ 0.3164 (7.91%)	142.47M
NKLANikola Corporation	$ 0.6526 (6.55%)	106.88M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M